LINC00665 and cholangiocarcinoma: The association between over-expression of LINC00665 and poor survival of patients has been verified in breast cancer [6], cholangiocarcinoma [9], gastric cancer [15], glioma [19], hepatocellular carcinoma [20], lung cancer [24], osteosarcoma [30], ovarian cancer [33], and prostate cancer [34] (Table 3).